Government · 2 deals
Every published round AEA Innovate took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| AlleSense | Series A | May 2026 | $5m | Participant | Startup Daily (29 May 2026), Dealroom, Startup Daily (28 May 2026) | |
| AlleSense | Unnamed stage | 4 Aug 2026 | $5m | Participant | Startup Daily |
Companies AEA Innovate has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| AlleSense | Biotech developing pathology imaging technology for early cancer detection | May 2026, Series A | 2 | 0 |
Fund closes reported for AEA Innovate, as distinct from the investments it has made.
Companies AEA Innovate has backed that another company then bought. An exit for the holding, not a deal AEA Innovate did.
Stories naming AEA Innovate. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech AlleSense, developing cancer pathology imaging tech, raised $5 million led by Welcome Ventures with Breakthrough Victoria and an AEA grant contributing.
La Trobe University spin-out AlleSense has secured $5 million to develop slide-based imaging for earlier cancer detection, led by Welcome Ventures with Breakthrough Victoria and the Australian Economic Accelerator's grant program also contributing.
Also Dealroom·Startup Daily